or Try an Advanced Search...

    Biotechnology Companies Stocks List

    Symbol Grade Name % Change
    RPRX D Royalty Pharma plc -0.95
    MYGN D Myriad Genetics, Inc. -1.45
    MGNX D MacroGenics, Inc. -1.53
    GNOM D Global X Genomics & Biotechnology ETF -0.67
    HBIO F Harvard Bioscience, Inc. 0.77
    CSBR F Champions Oncology, Inc. -0.51
    BLRX F BioLineRx Ltd. -4.17
    View As Page of Charts
    Related Industries: Agricultural Inputs Biotechnology Diagnostics & Research Medical Instruments & Supplies
    Related Stock Lists: Biotechnology Cancer Autoimmune Disease Biology Drug Development Medicine Pharmacology Acid Acute Myeloid Leukemia Antibodies Antibody Bank Biomarkers Biopharmaceutical Biopharmaceutical Development Biopharmaceutical Products Breast And Ovarian Cancer Cancer Care Cardiology Cell Biology

    Related ETFs - A few ETFs which own one or more of the above listed Biotechnology Companies stocks.

    Symbol Grade Name Weight
    GXTG C Global X Thematic Growth ETF 11.3
    ROYA A Tema Global Royalties ETF 5.59
    IHE D iShares U.S. Pharmaceutical ETF 4.59
    XPH D SPDR S&P Pharmaceuticals ETF 4.51
    PILL F Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF 3.86
    View all Biotechnology Companies ETFs...
    Compare ETFs
    Compare IHE to XPH Compare ROYA to PILL Compare ROYA to XPH

        Biotechnology Companies Stocks Recent News

        Date Stock Title
        May 7 MYGN Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business
        May 7 MYGN Myriad Genetics (NASDAQ:MYGN) shareholders have endured a 26% loss from investing in the stock five years ago
        May 6 MYGN Myriad Genetics Q1 2024 Earnings Preview
        May 6 HBIO Harvard Bioscience Q1 2024 Earnings Preview
        May 6 BLRX BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
        May 4 RPRX Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be $0.21
        May 3 MGNX MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
        May 2 RPRX Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
        Apr 30 MYGN Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024
        Related Industries: Agricultural Inputs Biotechnology Diagnostics & Research Medical Instruments & Supplies
        Related Stock Lists: Biotechnology Cancer Autoimmune Disease Biology Drug Development Medicine Pharmacology Acid Acute Myeloid Leukemia Antibodies Antibody Bank Biomarkers Biopharmaceutical Biopharmaceutical Development Biopharmaceutical Products Breast And Ovarian Cancer Cancer Care Cardiology Cell Biology
        Biotechnology Companies

        Browse All Tags